WP
ALLO icon

Woodline Partners’s Allogene Therapeutics ALLO Stock Holding History

Woodline Partners’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.54M Buy
3,501,078
+579
+0% +$1.16K 0.03% 550
2025
Q4 		$4.8M Sell
3,500,499
-860,109
-20% -$1.13M 0.02% 630
2025
Q3 		$5.41M Hold
4,360,608
– – 0.03% 547
2025
Q2 		$4.93M Hold
4,360,608
– – 0.03% 560
2025
Q1 		$6.37M Buy
4,360,608
+376
+0% +$709 0.04% 445
2024
Q4 		$9.29M Sell
4,360,232
-4,068
-0.1% -$10K 0.06% 361
2024
Q3 		$12.2M Buy
4,364,300
+5,311
+0.1% +$14.2K 0.1% 266
2024
Q2 		$10.2M Buy
4,358,989
+1,725,013
+65% +$5.09M 0.1% 246
2024
Q1 		$11.8M Buy
2,633,976
+56,476
+2% +$236K 0.11% 237
2023
Q4 		$8.27M Sell
2,577,500
-2,736,415
-51% -$7.76M 0.09% 250
2023
Q3 		$16.8M Buy
5,313,915
+415
+0% +$1.82K 0.2% 152
2023
Q2 		$26.4M Buy
5,313,500
+3,121,070
+142% +$16.9M 0.31% 94
2023
Q1 		$10.8M Sell
2,192,430
-729,032
-25% -$4.68M 0.15% 187
2022
Q4 		$18.4M Sell
2,921,462
-1,604,960
-35% -$14.9M 0.25% 125
2022
Q3 		$48.9M Sell
4,526,422
-1,333,257
-23% -$18.1M 0.68% 26
2022
Q2 		$66.8M Buy
5,859,679
+5,427,529
+1,256% +$48.2M 1.03% 8
2022
Q1 		$3.94M Sell
432,150
-67,945
-14% -$708K 0.06% 271
2021
Q4 		$7.46M Sell
500,095
-312,635
-38% -$5.52M 0.11% 234
2021
Q3 		$20.9M Buy
812,730
+127,975
+19% +$3.04M 0.34% 79
2021
Q2 		$17.9M Buy
684,755
+12,111
+2% +$345K 0.33% 81
2021
Q1 		$23.7M Buy
672,644
+105,105
+19% +$3.55M 0.53% 59
2020
Q4 		$14.3M Buy
567,539
+167,306
+42% +$5.45M 0.38% 83
2020
Q3 		$15.1M Buy
400,233
+271,605
+211% +$10.2M 0.49% 57
2020
Q2 		$5.51M Buy
+128,628
New +$4.65M 0.22% 106

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Woodline Partners's ALLO Position: Q1 2026 in Review

Woodline Partners increased its Allogene Therapeutics (ALLO) stake by 0.02% in Q1 2026, buying an estimated $1.16K and bringing the position to 3,501,078 shares worth $8.54M. The position accounts for 0.03% of the portfolio, ranked #550.

Woodline Partners first reported a position in ALLO in Q2 2020 and has held it in 24 quarters since. The position peaked at $66.8M in Q2 2022. 208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • Woodline Partners held 3,501,078 shares of Allogene Therapeutics worth $8.54M as of Q1 2026.
  • Woodline Partners bought 579 Allogene Therapeutics shares in Q1 2026, an estimated $1.16K.
  • Allogene Therapeutics made up 0.03% of Woodline Partners's portfolio in Q1 2026, its #550 holding.
  • Woodline Partners first reported a position in Allogene Therapeutics in Q2 2020 and has held it in 24 quarters since.
  • Woodline Partners's Allogene Therapeutics position peaked at $66.8M in Q2 2022.
  • 208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.